United Therapeutics (NASDAQ: UTHR) Price Target Raised Amidst Clinical Progress and Legal Settlements

Cantor Fitzgerald raises its price target for United Therapeutics (NASDAQ: UTHR) to $850 from $700. At the reported share price of $590.57, the new target is $259.43 higher, implying about 43.9% potential upside. A price target is an analyst’s estimate of where a stock may trade, not a guaranteed result.

United Therapeutics develops treatments for serious diseases, including pulmonary hypertension, a condition that raises blood pressure in the lungs. It also works on organs for transplant. The company opens its third designated pathogen-free facility in Houston, expanding its capacity to produce xenografts—animal organs intended for human transplant research. Its first such facility opened in Virginia in 2024 to supply clinical trials.

The FDA also clears United Therapeutics to begin a phase 2 trial of treprostinil SMI for people with pulmonary hypertension linked to chronic obstructive pulmonary disease. The study plans to assess safety and how well patients tolerate the treatment over 16 weeks, with approximately 40 participants. Clearance to run a trial does not mean the treatment is approved for sale.

United Therapeutics and Liquidia settle all six pending legal disputes between them. The agreement keeps Liquidia’s Yutrepia available to patients with pulmonary arterial hypertension but narrows the drug’s label. Liquidia will pay United Therapeutics $380.7 million in installments during 2026 and 2027, as highlighted by Zacks Investment Research.